Examkin

Soru

Zorluk: ZorEnd-of-Life and Palliative Care

A 71-year-old woman with widely metastatic breast cancer is admitted to the inpatient hospice unit for end-of-life care. She is actively dying and minimally responsive. Over the past 24 hours, she has experienced episodes of severe terminal delirium with agitation, which are currently being managed with scheduled haloperidol. Her family is now highly distressed by loud, gurgling respiratory sounds originating from her upper airway. Auscultation reveals coarse upper airway transmitted sounds with clear lung bases. Her respiratory rate is 14/min, and she shows no signs of air hunger, accessory muscle use, or labored breathing during quiet intervals. Which of the following is the most appropriate next step in the management of this patient's respiratory symptom?

  1. Administer intravenous glycopyrrolateCevap
  2. B
    Apply a transdermal scopolamine patch
  3. C
    Perform deep nasopharyngeal suctioning
  4. D
    Administer intravenous furosemide
  5. E
    Increase the dose of intravenous morphine

Cevap

Administer intravenous glycopyrrolate
The correct answer involves administering an anticholinergic medication that minimizes central nervous system side effects. Glycopyrrolate is a quaternary ammonium compound that is highly polar and therefore does not cross the blood-brain barrier. It effectively dries oropharyngeal secretions (resolving the 'death rattle') without risking the exacerbation of the patient's severe terminal delirium.

Adım Adım Çözüm

1
Identify the primary clinical symptom causing distress.
The patient has loud, gurgling upper airway noises, commonly known as a 'death rattle', caused by pooled oropharyngeal secretions in a dying patient who can no longer clear them.
Accurate symptom identification directs the choice of pharmacologic or non-pharmacologic intervention.
2
Evaluate the patient's concurrent conditions and clinical context.
The patient is actively dying and suffers from severe terminal delirium with agitation.
Concurrent conditions dictate which medications are safe and which are contraindicated based on side effect profiles.
3
Select the appropriate pharmacologic therapy while avoiding contraindications.
An anticholinergic agent is needed to dry secretions. Glycopyrrolate is selected because it is a quaternary amine that does not cross the blood-brain barrier.
Alternative anticholinergics like scopolamine or atropine are tertiary amines that penetrate the central nervous system and can severely exacerbate the patient's terminal delirium.

Anahtar Kavram

Management of terminal secretions ('death rattle') in the setting of concurrent terminal delirium requires quaternary amine anticholinergics (e.g., glycopyrrolate) that do not cross the blood-brain barrier.
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru